Diagnostics

Journal Browser

► Journal Browser

Diagnosis and Management of Gynecological Cancer

Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Clinical Laboratory Medicine".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 2331

Share This Special Issue

Special Issue Information

Dear Colleagues,

The diagnosis and treatment of gynecological cancer is an ever-evolving topic which follows technology and scientific developments. The introduction of new diagnostic methods and the advances of current imaging and pathology tools allow the precise characterization of tumors before treatment is started. The advent of new surgical platforms, the sentinel lymph node, and the molecular classification of gynecological cancers mean that treatments are increasingly individualized. Recent scientific updates, including the risk of adverse oncologic outcomes in cervical cancer treated with minimally invasive surgery, represent a push to find alternative solutions to surgical treatment for early-stage cervical cancer. The advent of new drugs and surgical techniques represents an important advancement in the management of ovarian cancer. Lastly, different detection modalities and analyses of sentinel lymph nodes can be applied for further implementing treatment strategies and defining prognoses in patients with gynecological cancers.

We look forward to receiving manuscripts on the diagnosis, treatment, and prognosis of patients with gynecological cancers.

Dr. Nicolò Bizzarri
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

cervical cancer
endometrial cancer
ovarian cancer
vulvar cancer
vaginal cancer
uterine cancer

Published Papers (2 papers)

Download All Papers

Research

Jump to: Other

13 pages, 1823 KiB

Open AccessArticle

Prognostic Significance of Preoperative NLR, MLR, and PLR Values in Predicting the Outcome of Primary Cytoreductive Surgery in Serous Epithelial Ovarian Cancer

by Anna Rebeka Kovács, Anita Sulina, Kincső Sára Kovács, Luca Lukács, Péter Török and Rudolf Lampé

Diagnostics 2023, 13(13), 2268; https://doi.org/10.3390/diagnostics13132268 - 4 Jul 2023

Cited by 3 | Viewed by 1132

Abstract

(1) The degree of cytoreduction achieved during primary debulking surgery (PDS) is an important prognostic factor for the survival of patients with epithelial ovarian cancer (EOC). Our aim was to investigate the prognostic value of preoperative laboratory parameters for the outcome of PDS. (2) We analyzed the preoperative laboratory parameters of 150 serous EOC patients who underwent PDS between 2006 and 2013. Receiver operating characteristic (ROC) curve analysis was used to determine the optimal cut-off values of the variables for predicting the PDS outcome. We used binary logistic regression to examine the independent predictive value of the factors for incomplete cytoreduction. (3) Among the parameters, we established optimal cut-off values for cancer antigen (Ca)-125, neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and platelet-to-lymphocyte ratio (PLR) to predict the outcome of PDS. The results of binary logistic regression showed that stage (FIGO III-IV), MLR (>0.305), and Ca-125 (>169.15 kU/L) were independent significant predictors of the degree of tumor reduction achieved during PDS. (4) In the future, MLR, especially in combination with other parameters, may be useful in determining prognosis and selecting the best treatment option (PDS or neoadjuvant chemotherapy + interval debulking surgery) for ovarian cancer patients. Full article

(This article belongs to the Special Issue Diagnosis and Management of Gynecological Cancer)

► Show Figures

Figure 1

Other

Jump to: Research

14 pages, 3077 KiB

Open AccessSystematic Review

Prognostic Significance of Programmed Cell Death Ligand 1 Expression in High-Grade Serous Ovarian Carcinoma: A Systematic Review and Meta-Analysis

by Jeongwan Kang, Kang Min Han, Hera Jung and Hyunchul Kim

Diagnostics 2023, 13(20), 3258; https://doi.org/10.3390/diagnostics13203258 - 19 Oct 2023

Viewed by 808

Abstract

(1) Background: High-grade serous ovarian carcinoma (HGSOC) is an aggressive subtype of ovarian cancer. Recent advances have introduced prognostic markers and targeted therapies. Programmed cell death ligand 1 (PD-L1) has emerged as a potential biomarker for HGSOC, with implications for prognosis and targeted therapy eligibility; (2) Methods: A literature search was conducted on major databases, and extracted data were categorized and pooled. Subgroup analysis was performed for studies with high heterogeneity. (3) Results: Data from 18 eligible studies were categorized and pooled based on PD-L1 scoring methods, survival analysis types, and endpoints. The result showed an association between high PD-L1 expression and a favorable prognosis in progression-free survival (HR = 0.53, 95% CI = 0.35–0.78, p = 0.0015). Subgroup analyses showed similar associations in subgroups of neoadjuvant chemotherapy patients (HR = 0.6, 95% CI = 0.4–0.88, p = 0.009) and European studies (HR = 0.59, 95% CI = 0.42–0.82, p = 0.0017). In addition, subgroup analyses using data from studies using FDA-approved PD-L1 antibodies suggested a significant association between favorable prognosis and high PD-L1 expression in a subgroup including high and low stage data in overall survival data (HR = 0.46, 95% CI = 0.3–0.73, p = 0.0009). (4) Conclusions: This meta-analysis revealed a potential association between high PD-L1 expression and favorable prognosis. However, caution is warranted due to several limitations. Validation via large-scale studies, with mRNA analysis, whole tissue sections, and assessments using FDA-approved antibodies is needed. Full article

(This article belongs to the Special Issue Diagnosis and Management of Gynecological Cancer)

► Show Figures